Neutraceutical business now has negative market ca Take NTB's $102M market cap (as of 1pm today), back out it's 61% interest in APO (CaPre, which is holding out OK) and its cash (estimated at $40M), leaves about negative $40M of market cap for the NKO business.
So much for the 'sum of the parts" discussion.
If this value was even remotely accurate, management should clear up the plant debris and pave it over, and invest the $40M in APO, etc. But what about the product, patents, customers, etc......
The current SP seems to imply zero insurance recovery - which is crazy.
One strong possibility is to sell (or partner) the NKO technology to an established, well capitalized third party. Would generate a minimum $100M of market value right away.
Once tax loss selling season is over (Dec 24th in Canada, Dec 26th in the US), things should move back upward.